SAB Biotherapeutics's total assets for Q1 2026 were $248.47M, an increase of 43.78% from the previous quarter. SABS total liabilities were $21.22M for the fiscal quarter, a -0.44% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.